The effect of Kampo medicine for prevention of chronic subdural hematoma recurrence-prosepective study

The effect of Kampo medicine for prevention of chronic subdural hematoma recurrence-prosepective study - The effect of Kampo medicine for prevention of chronic subdural hematoma recurrence-prosepective study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027747

Enrollment

300

Registered

2017-06-19

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic subdural hematoma

Interventions

Administration of goreisan Administration of saireito No administration of Kampo medicine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patient aged 20 and over 2.Patinet diagnosed as primary chronic subdural hematoma and performed the operation of drainage 3.Patinent with self-sufficient

Exclusion criteria

Exclusion criteria: 1.Patient with severe dementia 2.Patient unable to take Kampo medicine 3.Bedridden patient

Design outcomes

Primary

Measure	Time frame
Recurrence required operation	—

Secondary

Measure	Time frame
Side effect	—

Countries

Japan

Contacts

Public ContactHiroaki Matsumoto

Cerebrovascular Research Institute, Eishokai Yoshida Hospital Department of Neurosurgery

hiroaki-matsu@umin.ac.jp078-576-2773

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026